HANOVER, Md., Sept. 19, 2016 -- The KEYW Holding Corporation (NASDAQ:KEYW) announced today that it has received a five-year contract from Leidos Inc. to provide global airborne collection services valued at $268.5 million if all options are exercised to support the Army Geospatial Center’s High-Resolution, 3-D Geospatial Information program. The contract comprises a base period of performance valued at $49.5 million and four option years.
KEYW's high-resolution imaging technology has evolved from urban counter-IED missions to wide-area, high-resolution, three-dimensional geospatial information (HR3DGI) missions around the world. KEYW also develops and operates a range of additional capabilities including synthetic aperture radar, radio-frequency survey, hyperspectral imaging and other custom-built sensors. For more information, please visit www.keywcorp.com.
About KEYW
KEYW is a total solutions provider for the Intelligence Community’s toughest challenges. We support the collection, processing, analysis and dissemination of information across the full life cycle of the Intelligence Community’s mission. We employ and challenge the most talented professionals in the industry with solving such complex problems as preventing cyber threats, transforming data into intelligence and combating global terrorism. For more information contact KEYW, 7740 Milestone Parkway, Suite 400, Hanover, Maryland 21076; Phone 443-733-1600; Fax 443-733-1601; E-mail [email protected]; or on the Web at www.keywcorp.com.
Forward-Looking Statements: Statements made in this press release that are not historical facts constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include but are not limited to statements about our future expectations, plans and prospects, and other statements containing the words “estimates,” “believes,” “anticipates,” “plans,” “expects,” “will,” “potential,” “opportunities,” “if,” and similar expressions. Our actual results, performance or achievements or industry results may differ materially from those expressed or implied in these forward-looking statements. These statements involve numerous risks and uncertainties, including but not limited to those risk factors set forth in our Annual Report on Form 10-K, dated and filed March 15, 2016 with the Securities and Exchange Commission (SEC) as required under the Securities Act of 1934, and other filings that we make with the SEC from time to time. Due to such uncertainties and risks, readers are cautioned not to place undue reliance on such forward-looking statements. KEYW is under no obligation to (and expressly disclaims any such obligation to) update or alter its forward-looking statements whether as a result of new information, future events or otherwise.
Media Contact: Heather Williams 443-733-1600 Investor Contact: Chris Donaghey 443-733-1600


CTOC Adds 3,000 Doctors, 500 Hospitals Ahead of Liquidity Push
TSMC Japan's Second Fab to Produce 3nm Chips by 2028
Trump Administration Plans 100% Tariffs on Pharmaceutical Imports
Europe's Aviation Sector on Track to Meet 2025 Green Fuel Mandate
Nomura Upgrades PDD Holdings to Buy, Calls Stock Too Cheap to Ignore
Bank of America's $72.5M Epstein Settlement: What You Need to Know
Novartis to Acquire Biotech Firm Excellergy in $2 Billion Deal
Norma Group Posts Revenue Decline in 2025, Eyes Modest Recovery in 2026
Star Entertainment Secures $390M Refinancing Deal to Stabilize Operations
Nike Beats Q3 Estimates but China Weakness and Margin Pressure Weigh on Outlook
Cathay Pacific Holds Firm on Flight Capacity Amid Middle East Conflict and Rising Fuel Costs
KPMG UK Cuts 440 Audit Jobs Amid Low Attrition and Cooling Professional Services Demand
Apple Turns 50: From Garage Startup to AI Crossroads
Microsoft Eyes $7B Texas Energy Deal to Power AI Data Centers
BlackRock CEO Larry Fink Earns $37.7 Million in 2025 Amid Record Growth
Fonterra Admits Anchor Butter "Grass-Fed" Label Misled Consumers After Greenpeace Lawsuit
Eli Lilly and Insilico Medicine Forge $2.75 Billion AI-Driven Drug Discovery Deal 



